FELECIA ABDELFATTAH: Open Payments
NPI 1497768451 · BRISTOL, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,208 in 136 payments from 13 companies in 2025. Trend: 2023 $986 · 2024 $1,298 · 2025 $2,208
Food & beverage: $2,208
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $423 |
| Neurocrine BioSciences, Inc. | 21 | $345 |
| Vanda Pharmaceuticals Inc. | 16 | $249 |
| Teva Pharmaceuticals USA, Inc. | 12 | $243 |
| Janssen Pharmaceuticals, Inc | 14 | $238 |
| Lundbeck LLC | 14 | $205 |
| Alkermes, Inc. | 12 | $153 |
| Otsuka America Pharmaceutical, Inc. | 7 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $81 |
Products named: VRAYLAR, INGREZZA, HETLIOZ, INVEGA SUSTENNA, REXULTI, UZEDY, ARISTADA, ABILIFY MAINTENA.
Industry payments across TN — which companies pay providers there.
